NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus

European Heart Journal

Volumn 29, Issue 18, 2008, Pages 2259-2264

  Huelsmann, Martin ^a   Neuhold, Stephanie ^a   Strunk, Guido ^b   Moertl, Deddo ^a   Berger, Rudolf ^a   Prager, Rudolf ^c   Abrahamian, Heidemarie ^c   Riedl, Michaela ^a   Pacher, Richard ^a   Luger, Anton ^a   Clodi, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF ECONOMICS AND BUSINESS   (Austria)

^c Hietzing Hospital   (Austria)

Author keywords

Cardiovascular risk; Diabetes mellitus; Natriuretic peptides; Prognosis

Indexed keywords

NATRIURETIC FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE;

BIOLOGICAL MARKERS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 52449109450     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn334     Document Type: Article

References (30)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979;59:8-13.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
3. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-1426.
4. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of Hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-420.
5. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828.
6. Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, Caspi A, Faraggi D, Livschitz S. Reduced glomerular filtration rate in asymptomatic diabetic patients. J Am Coll Cardiol 2004;44:2142-2148.
7. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007;30:1248-1254.
8. Buse JB, Ginsberg HN, Bakris GL. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-172.
9. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;30:321-328.
10. Mc Donagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJV, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
11. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-135.
12. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Ramachandran SV. Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
13. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-1941.
14. Dawson A, Jeyaseelan S, Morris AD, Struthers AD. B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol 2005;96:933-934.
15. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006;49:2256-2262.
16. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156-163.
17. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clopton P, Krishnaswamy P, Morrison LK, Chiu A, Gardetto N, Mudaliar S, Edelmann SV, Henry RR, Maisel AS. Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes mellitus. Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004;44:1047-1052.
18. Christoffersen C, Hunter I, Jensen A, Goetze J. Diabetes and the endocrine heart. Eur Heart J 2007;28:2427-2429.
19. Gaede P, Vedel P, Larsen N, Jensen GVD, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
20. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-795.
21. Fonarow GC, Srikanthan P, Costanzo MA, Cintron GB, Lopatin M. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108927 patients in the acute decompensated heart failure registry. Am Heart J 2007;153:74-81.
22. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006;151:76-83.
23. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1940.
24. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006;151:91.e1-91.e6.
25. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439-1444.
26. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879-1884.
27. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth O, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J 2005;26:1115-1140.
28. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptides in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-1539.
29. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-b-type peptide and long-term mortality in acute coronary syndrome. Circulation 2002;106:2913-2918.
30. Cook N. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction. Circulation 2007;115:928-935.